CRP and inflammatory bowel disease: In 2021, the Selecting Therapeutic Targets in IBD [STRIDE-II] initiative proposed short- and long-term treatment targets for adult and paediatric patients with inflammatory bowel disease [IBD].3 The recommended short- and intermediate-term targets in children included achieving symptomatic clinical remission, normalisation of biomarkers such as C-reactive protein [CRP] and faecal calprotectin [FCP], and restored growth.